Search results | central nervous system

Reports

Central Nervous System Partnering Terms and Agreements

The Central Nervous System Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the central nervous system (cns) partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Nervous GlaxoSmithKline pulls cash out of Eurozone to avoid crisis

Written by Julia Kollewe for The Guardian. GlaxoSmithKline has been pulling cash out of some eurozone countries in case the debt crisis takes a turn for the worse. Speaking at the drugmaker’s annual results presentation in London, the recently knighted chief executive Sir Andrew Witty said in the past year the company had been withdrawing more »

Genmab: Rapidly progressing in the field of antibodies

Genmab is an internationally recognised biotechnology company developing human antibody therapeutics primarily for cancer.

Orphan diseases partnering: A lucrative step for drug makers

By Shamini Thiagarajan Increased collaborations, big pharma involvements, venture capital investments, and medical/technological breakthroughs are together changing the landscape of research and development in orphan diseases.

Life Science M&A Deal Trends in Q2, 2014

By Steve Poile                                     With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.

Takeda Pharmaceuticals

Takeda Pharmaceuticals is a top pharmaceutical company based in Osaka, Japan

Valeant

Valeant Pharmaceuticals is a top pharmaceutical company based in Montreal, Quebec, Canada

Life Science M&A Deal Trends in Q1, 2014

With 85 deals announced, the first quarter of 2014 started strongly for life science M&A

Sanofi

Sanofi is a top pharmaceutical company based in Paris, France

Ranbaxy

Ranbaxy Laboratories is a top pharmaceutical company based in Haryana, India

UCB

UCB is a top pharmaceutical company based in Brussels, Belgium

Events

Sorry, your search returned no results.


Deals

Nervous GlaxoSmithKline pulls cash out of Eurozone to avoid crisis

Written by Julia Kollewe for The Guardian. GlaxoSmithKline has been pulling cash out of some eurozone countries in case the debt crisis takes a turn for the worse. Speaking at the drugmaker’s annual results presentation in London, the recently knighted chief executive Sir Andrew Witty said in the past year the company had been withdrawing more »

Teva acquires Auspex for $3.2 billion

Teva and Auspex Pharmaceuticals have entered into a definitive merger agreement

Minerva Neurosciences bags $31 million funding

Minerva Neurosciences will raise approximately $31 million of gross proceeds in a private placement offering to several institutional investors

Concordia Healthcare stumps up $1.2bn for Covis Pharma assets

Concordia Healthcare has entered into a definitive asset purchase agreement to acquire substantially all of the commercial assets of privately held Covis Pharma and Covis Injectables for US$1.2 billion

Alkahest banks $37.5 million in Grifols pact

Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging

RegenxBio brings in $30 million series C

REGENXBIO announced the completion of a $30 million Series C financing

Rush University Medical Center receives $42 million in royalty financing

DRI Capital and Rush University Medical Center announced that Drug Royalty III, DRI has purchased Rush’s royalties relating to worldwide sales of Ampyra for approximately $42 million.

ArmaGen signs a pharma licensing deal with Shire

Shire and ArmaGen announced a worldwide pharma licensing and collaboration agreement for AGT-182.

Merck and Bionomics sign a pharma licensing deal for $526 million

Bionomics has entered into an exclusive research collaboration and pharma licensing Agreement with Merck for its BNC375 research program targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions.

Sage Therapeutics gets $38 million in series C financing

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the successful completion of a $38 million Series C financing.